Scholar Rock Holding Co. (NASDAQ:SRRK) Stake Reduced by Values First Advisors Inc.

Values First Advisors Inc. trimmed its holdings in Scholar Rock Holding Co. (NASDAQ:SRRK - Free Report) by 30.2% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 18,234 shares of the company's stock after selling 7,885 shares during the period. Values First Advisors Inc.'s holdings in Scholar Rock were worth $788,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also modified their holdings of the company. GAMMA Investing LLC lifted its stake in shares of Scholar Rock by 51.8% in the 4th quarter. GAMMA Investing LLC now owns 788 shares of the company's stock valued at $34,000 after purchasing an additional 269 shares in the last quarter. JPMorgan Chase & Co. lifted its position in Scholar Rock by 1.0% during the 3rd quarter. JPMorgan Chase & Co. now owns 38,726 shares of the company's stock worth $310,000 after acquiring an additional 379 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its position in Scholar Rock by 21.6% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,895 shares of the company's stock worth $25,000 after acquiring an additional 514 shares in the last quarter. Nisa Investment Advisors LLC lifted its position in Scholar Rock by 1,321.8% during the 4th quarter. Nisa Investment Advisors LLC now owns 1,109 shares of the company's stock worth $48,000 after acquiring an additional 1,031 shares in the last quarter. Finally, Cinctive Capital Management LP lifted its position in Scholar Rock by 7.2% during the 3rd quarter. Cinctive Capital Management LP now owns 42,902 shares of the company's stock worth $344,000 after acquiring an additional 2,869 shares in the last quarter. 91.08% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several equities analysts recently commented on the company. Wedbush reissued an "outperform" rating and set a $47.00 price target on shares of Scholar Rock in a research report on Wednesday, January 29th. HC Wainwright boosted their price target on Scholar Rock from $40.00 to $50.00 and gave the stock a "buy" rating in a research report on Tuesday, November 26th. Finally, Truist Financial boosted their price target on Scholar Rock from $36.00 to $45.00 and gave the stock a "buy" rating in a research report on Monday, November 25th. Six investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat.com, Scholar Rock presently has an average rating of "Buy" and an average price target of $40.43.

Scholar Rock Stock Down 1.5 %

SRRK stock traded down $0.56 during midday trading on Friday, hitting $37.07. 518,332 shares of the company's stock were exchanged, compared to its average volume of 927,639. The company has a current ratio of 3.88, a quick ratio of 3.88 and a debt-to-equity ratio of 0.63. Scholar Rock Holding Co. has a 12-month low of $6.76 and a 12-month high of $46.98. The firm has a 50 day moving average price of $42.34 and a 200-day moving average price of $27.37. The stock has a market capitalization of $3.47 billion, a price-to-earnings ratio of -15.77 and a beta of 0.50.

Insider Activity

In other news, major shareholder Public Equities L.P. Invus sold 409,433 shares of the business's stock in a transaction that occurred on Monday, November 25th. The stock was sold at an average price of $38.49, for a total value of $15,759,076.17. Following the completion of the sale, the insider now directly owns 10,850,005 shares in the company, valued at approximately $417,616,692.45. The trade was a 3.64 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Edward H. Myles sold 12,539 shares of the business's stock in a transaction that occurred on Thursday, January 16th. The shares were sold at an average price of $44.20, for a total value of $554,223.80. Following the completion of the sale, the chief financial officer now owns 148,549 shares of the company's stock, valued at $6,565,865.80. This trade represents a 7.78 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 458,974 shares of company stock worth $17,948,788. 19.20% of the stock is currently owned by insiders.

Scholar Rock Company Profile

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies.